Lamivudine Adjusted
Loading...
References
- NA. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.. Journal of hepatology, 2025
- Rajesh T Gandhi. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel.. JAMA, 2025
- Matthew Spencer. Antiretroviral therapy in people with HIV and end-stage kidney disease.. AIDS (London, England), 2025
- NA. KASL clinical practice guidelines for management of chronic hepatitis B.. Clinical and molecular hepatology, 2022
- H. Wen. Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function. Expert Review of Clinical Pharmacology, 2022
- Anna L Funk. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.. The Lancet. Infectious diseases, 2021
- K. Mounzer. To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment. AIDS, 2021
- M. Tan. Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?. HIV Medicine, 2019
- B. Kayaaslan. Adverse effects of oral antiviral therapy in chronic hepatitis B. World Journal of Hepatology, 2017
- Briann Fischetti. Real-World Experience With Higher-Than-Recommended Doses of Lamivudine in Patients With Varying Degrees of Renal Impairment. Open Forum Infectious Diseases, 2017
- C. Pipili. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Alimentary Pharmacology & Therapeutics, 2014
- A. Lok. Long-term safety of lamivudine treatment in patients with chronic hepatitis B.. Gastroenterology, 2003
- A. Heald. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrobial Agents and Chemotherapy, 1996